Another promising dual-PPAR α/γ agonist for NAFLD is lobeglitazone, which has demonstrated a positive therapeutic effect in T2DM patients (see Section 3). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.